Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
The acquired ANDAs represent a market opportunity of about US$ 38 million in the USA
Apollo has also announced plans to add over 4,300 beds in the next five years with an investment of over Rs. 7,600 crore
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
Subscribe To Our Newsletter & Stay Updated